ITM Isotope Technologies Munich SE

ITM Isotopen Technologien München AG

General information

ITM Isotope Technologies Munich SE
Walther-von-Dyck-Strasse 4
85748 Garching / Munich, Bavaria
Germany

Contact person: Steffen Schuster, Chief Executive Officer
Company main phone: +49 (89) 32989866000
Company main fax: +49 (89) 32989866061
Website: https://itm-radiopharma.com

Year founded:	2004
Source of foundation:	Independent foundation

Corporate description / mission:
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.

State of ownership: Private / independent
Headquarters: HQ: Yes

Categorization

Sector:

Pharma (fully integrated)

Subsector:

Antibodies
Peptides
Other

Primary therapeutic areas:

Diseases of the ear / otology
Neoplasms / cancer / oncology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

Manufacturer
R&D
Supplier / Distributor

Customer segments:

Large biotech & big pharma

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	11
Phase I:	4
Phase III:	4
On the market:	1

Description of products:
ITM-41
ITM-52
ITM-55D
ITM-22 etc.

Collaborations & Clients

Partnering strategy / collaborations:
The company is always seeking innovative drug discovery partnerships, ideally fusing their target know-how with their leading radioisotope platform technologies to develop next generation diagnostic and therapeutic agents that will help fight serious and difficult to treat cancer diseases.